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ABS T RAC T

Objectives: A new patient-reported outcome (PRO) instrument to
measure fatigue symptoms and impacts in relapsing multiple sclerosis (RMS) was developed in a qualitative stage, followed by psychometric validation and migration from paper to an electronic
format. Methods: Adult patients with relapsing-remitting multiple
sclerosis (RRMS) were interviewed to elicit fatigue-related symptoms
and impacts. A draft questionnaire was debriefed in cognitive interviews with further RRMS patients, and revised. Content confirmation interviews were conducted with patients with progressiverelapsing multiple sclerosis (PRMS) and relapsing secondaryprogressive multiple sclerosis (RSPMS). Psychometric analyses used
data from adult patients with different RMS subtypes and matched
non-RMS controls in a multicenter, observational study. After item
reduction, the final instrument was migrated to a smartphone (eDiary)
and usability was confirmed in interviews with additional adult RMS
patients. Results: The qualitative stage included 37 RRMS, 5 PRMS, and
5 RSPMS patients. Saturation of concepts was reached during concept
elicitation. Cognitive interviews confirmed that participants understood the instructions, items, and response options of the

Introduction
Fatigue is one of the most common symptoms of multiple sclerosis (MS),1e3 a chronic autoimmune disorder of the central nervous system.4 Often described as a feeling of extreme mental or
physical exhaustion, MS-related fatigue has far-reaching effects
on quality of life, employment, and productivity,5e7 imposing
limitations independently of MS-related physical disability and
depression.8
Given the subjective nature of fatigue, the effect of treatment
on fatigue in MS is best assessed via a patient-reported outcome
(PRO) instrument.9 Such a tool would also be valuable in clinical

instrumentdnamed FSIQ-RMSdas intended. Psychometric validation
included 164 RMS and 74 control patients. Internal consistency and
testeretest reliability were demonstrated. The symptoms domain
discriminated along the RMS symptom-severity continuum and between patients and controls. Patients were able to attribute fatiguerelated symptoms to RMS. Usability and conceptual equivalence of
the eDiary were confirmed (n ¼ 10 participants). Conclusions: With 7
symptom items and 13 impact items (in 3 impacts subdomains:
physical, cognitive and emotional, and coping) after item reduction,
the FSIQ-RMS is a comprehensive, valid, and reliable measure of
fatigue-related symptoms and impacts in RMS patients.
Keywords: fatigue, patient-reported outcome, relapsing multiple sclerosis, symptoms
Copyright © 2018, ISPOReThe Professional Society for Health Economics
and Outcomes Research. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).

practice, as MS guidelines and proposed quality-of-care measures
call for fatigue assessment using a PRO instrument with demonstrated consistency, reliability, and validity.10,11 The 2009 Food
and Drug Administration (FDA) PRO guidance, the FDA's 2015
roadmap to patient-focused outcome measurement in clinical
trials, and the 2015 recommendations from the ISPOR Clinical
Outcomes AssessmentdEmerging Good Practices for Outcomes
Research Task Force all emphasize the need to document the
content and construct validity, reliability, and sensitivity to
change of a PRO instrument.12e14
Although available PRO instruments have been used to
measure fatigue in MS patients,10,15e20 review of their

* Address correspondence to: Stacie Hudgens, Clinical Outcomes Solutions, 1790 East River Road, Suite #205, Tucson, AZ 85718, USA.
E-mail: stacie.hudgens@clinoutsolutions.com
1098-3015 - see front matter Copyright © 2018, ISPOReThe Professional Society for Health Economics and Outcomes Research. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jval.2018.11.007
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measurement properties suggests shortcomings in terms of
current standards for PRO instrument development. For
instance, the 9-item Fatigue Severity Scale (FSS) and the 21-item
Modified Fatigue Impact Scale (MFIS) do not fit the assumption of
unidimensionality, and so studies using their global scores may
need to be reevaluated.21,22
A primary requirement is to develop and validate a PRO instrument in the disease-specific target patient population for
intended use. The clinical course of MS broadly falls into relapsing and progressive forms (RMS and PMS, respectively).23
Three RMS subtypes are recognized.23e25 Relapsing-remitting
MS (RRMS), seen in approximately 80% to 85% of MS patients,
is characterized by acute exacerbations with full or partial recovery, and patients are generally stable between exacerbations.
Progressive-relapsing MS (PRMS), which afflicts roughly 5% of MS
patients, is marked by progression starting at disease onset, with
occasional relapses. Relapsing secondary-progressive MS
(RSPMS) gradually progresses later (after a median of 20 years) in
the disease course of approximately 65% to 70% of RRMS
patients.
As symptoms and their impacts could differ among these
various forms of MS, a PRO instrument should be validated in the
specific MS subtypes for which it will be used. A unidimensional
version of the FIS (U-FIS) has been developed to address the
multidimensionality of the original 40-item Fatigue Impact Scale
(FIS) and the MFIS,17,26 but some participants in its validation
research were recruited from patient organizations rather than
clinical centers, precluding confirmation of all participants' MS
diagnoses or their type of MS. Some other MS-specific fatigue
questionnaires, such as the FSS,15 were developed in patients with
PMS rather than RMS, which may affect their applicability as
outcome measures in RMS.
Another issue is whether a questionnaire comprehensively
measures MS symptoms and their impact; for example, the FSS
does not include items regarding cognitive fatigue,27 whereas the
FIS and MFIS assess the impact of symptoms on patient functioning, rather than measuring the severity of the symptoms
themselves.2,10,16
The objective of the present research was to address limitations of existing MS-specific instruments by developing a new,
content-valid, concise PRO instrument to assess fatigue symptoms relevant to patients within the spectrum of RMS and the
relevant impact of these symptoms on patients' lives, in accordance with the FDA PRO guidance.

Literature Review

Methods

Stage 2: cognitive interviews in RRMS

Overview
Development and psychometric validation of the new PRO instrument was conducted in 6 research stages, preceded by a
literature review (Fig. 1). Development of the draft questionnaire
was based on qualitative research in patients with RMS, including
concept elicitation and cognitive interviews (n ¼ 17 and 20,
respectively) in patients with RRMS, and content confirmation
interviews in patients with PRMS (n ¼ 5) and RSPMS (n ¼ 5).
Finalization of the new instrument and psychometric validation
analyses were based on data gathered in an observational study, a
real-world cross-sectional study, and a study to confirm the conceptual equivalence and usability of an electronic version of the
questionnaire.
All study-stage protocols were approved by centralized Institutional Review Boards, and all participants provided written
informed consent. All interviews were conducted by experienced
interviewers trained in the use of semistructured interview guides
specific to each study stage.

Literature reviews were conducted to identify evidence on fatiguerelated symptoms of RMS and their impacts. Relevant data were
used to inform development of preliminary conceptual frameworks for RMS symptoms and impacts, which in turn were used to
inform the concept elicitation interview guides. Searches were
conducted in Medline and covered a 10-year period for RRMSrelated searches (January 2000 to September 2010) and for subsequent searches pertaining to PRMS and RSPMS (January 2002 to
February 2012).

Qualitative Research
Stage 1: concept elicitation interviews in RRMS
Face-to-face concept elicitation interviews in patients with RRMS
were conducted to identify and describe fatigue-related symptoms and impacts from the patient perspective. The FIS was also
cognitively debriefed to determine the extent to which it may
assess RRMS symptoms and impacts and therefore be fit for purpose as an efficacy endpoint measure.
In these concept elicitation interviews, each participant was
asked open-ended questions to spontaneously elicit fatiguerelated symptoms of RRMS and their impacts as experienced by
the participant. Probing questions were posed if the initial openended queries did not elicit an explicit description of a fatiguerelated symptom or impact.
After qualitative analysis of the interview transcripts, concept
saturation was assessed. Saturation was considered to be achieved at the point at which no new, relevant concepts emerged
from subsequent interviews. A sample size of 15 was anticipated
to be sufficient to achieve saturation.28 Two additional participants were recruited to account for no-shows or cancellations.
As described in the Results, the FIS would have required too
many modifications to attain content validity in an RRMS population. Therefore, a new PRO instrument to assess fatigue-related
symptoms of RRMS and their impacts was drafted by the investigators based on the concepts spontaneously elicited in interviews. After the preliminary conceptual framework, the
instrument comprised a symptoms domain with a 24-hour recall
period and an impacts domain with a 7-day recall period. Concepts reported by more than 5 (>29.4%) of the 17 participants were
selected for inclusion in the initial paper questionnaire. The new
instrument was named the “Fatigue Symptoms and Impacts
QuestionnairedRelapsing Remitting Multiple Sclerosis” (FSIQRRMS).

Face-to-face cognitive interviews were conducted to assess the
relevance, comprehensibility, acceptability, and comprehensiveness of its items, in addition to the interpretability and appropriateness of instructions, response options, and the recall period of
the FSIQ-RRMS. These cognitive interviews included 20 patients
with RRMS who had not been included in stage 1.
An item was subject to revision if at least 5 (25.0%) of the 20
respondents gave consistent recommendations for its change (eg,
rewording or deletion), demonstrated difficulty interpreting it, or
did not interpret it as intended. The same threshold was applied
for the addition of suggested new items to the questionnaire.

Stage 3: content confirmation interviews in PRMS and RSPMS
After stage 2, it was decided to expand the target population for
the new PRO instrument to encompass a broader range of RMS
patients. One-on-one content confirmation interviews were conducted in patients with PRMS or RSPMS to test the understandability, comprehensiveness, and relevance of the instrument in
these RMS subtypes.
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Literature review on RRMS

Preliminary RRMS
conceptual framework

Stage 1: Concept elicitation
interviews
(RRMS, n = 17)

Stage 3: Content confirmation
interviews
(PRMS, n = 5; RSPMS, n = 5)
PRO renamed FSIQ-RMS v1
Stage 4: Psychometric validation
in observational study
(RRMS, n = 139; PRMS, n = 8;
RSPMS, n = 18; controls, n = 74)

Draft PRO: FSIQ-RRMS v1
Item analysis, content confirmation
Stage 2: Cognitive interviews
(RRMS, n = 20)

PRO revision: FSIQ-RMS v2
Final scoring algorithm

PRO revision: FSIQ-RRMS v2

Mixed methods analysis

Stage 5: Real-world study
(RRMS, n = 149; RSPMS, n = 5)

Reliability/validity analysis,
attribution analysis

PRO revision: FSIQ-RRMS v3

Final FSIQ-RMS®
paper version

Preliminary PRMS & RSPMS
conceptual frameworks

Stage 6: eDiary migration &
usability study
(RRMS, n = 8; RSPMS, n = 2)

Literature review on PRMS,
RSPMS

Revised FSIQ-RMS® eDiary

Future research:
Responsiveness & meaningful
change in Phase 3 trials:
OPTIMUM and POINT

Fig. 1 – Study flow. MS, multiple sclerosis; PRO, patient-reported outcome; PRMS, progressive-relapsing MS; RRMS,
relapsing-remitting MS; RSPMS, relapsing secondary-progressive MS.

Concept elicitation and cognitive interviews were conducted
using semistructured interview guides based on preliminary
conceptual frameworks developed for RSPMS and PRMS fatiguerelated symptoms and impacts. Interview findings indicated
that no revisions were required for application of the PRO instrument to patients with PRMS and RSPMS. The instrument was
renamed the “Fatigue Symptoms and Impacts QuestionnairedRelapsing Multiple Sclerosis” (FSIQ-RMS).

Psychometric Validation
Stage 4: observational study
Psychometric validation was performed in an observational study
that also included a control group of non-MS patients to demonstrate the ability of RMS patients to attribute fatigue symptoms to
their disease (n ¼ 164 patients with RMS þ 74 controls).
Psychometric analyses included tests of item response and
dimensionality, Rasch and exploratory factor analyses to assess
content validity, and analyses of construct validity, internal consistency reliability, and testeretest reliability. These analyses
were followed by an attribution analysis and development of a
scoring algorithm. After item reduction, the final version of the
questionnaire underwent confirmatory factor analysis, Rasch
analysis (only conducted on the unidimensional domain; ie,
symptoms), known-groups analysis (only for the symptoms
domain because the focus of the instrument was to be able to
support a PRO labeling claim for symptoms), and assessments of
concurrent and discriminant validity and of internal consistency
and testeretest reliability (for symptoms and impacts domains).
In the 12-week study period, patients with RMS were instructed to complete the paper version of the FSIQ-RMS at home (apart

from day 1) during 2 intervals: interval 1, from days 1 to 8, where
day 1 was used to collect baseline data on the symptoms and
impacts items, whereas days 2 to 8 were the first full week of
completion of the instrument, and interval 2, from days 80 to 86.
Participants were instructed to complete the symptoms domain
daily and the impacts domain on days 1, 8, and 86.
Additional PRO questionnaires had to be completed at 3 site
visits. Visit 1 occurred on day 1, whereas visits 2 and 3 could occur
within a 3-day window after completion of intervals 1 and 2 to
accommodate participants' scheduling conflicts. Additional instruments administered included the Medical Outcomes Study
RAND-3629 at visits 1 and 3, and Patient Global Impression of
Severity (PGI-S) scales30 modified for RMS and fatigue and the
MFIS10 at visits 1, 2, and 3. Clinicians completed the Expanded
Disability Status Scale (EDSS)31 at visit 1, and a Clinician Global
Impression of Change (CGI-C)32 at visits 2 and 3.
Control participants without an MS diagnosis completed an
adaption of the FSIQ-RMS with all references to RMS removed, at
home from days 1 to 7 with a site visit at day 1. Control participants were patients presenting for an acute condition or a
checkup and were required to meet the eligibility criteria
described in Table 1. Controls were individually matched to RMS
patients by sex, age group (in 10-year age cohorts), and race or
ethnicity.

Stage 5: real-world study in RMS
Originally developed in US English, the FSIQ-RMS was translated
and linguistically validated in 45 language versions (following the
Principles of Good Practice for the Translation and Cultural
Adaptation Process for PRO Measures33), including German. As an
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Table 1 – Patient eligibility criteria
Study stage
RMS patients
All stages

Inclusion criteria

Exclusion criteria

RMS diagnosis as defined by the revised
McDonald Diagnostic Criteria for MS
Completed written ICF
Ambulatory
Fluent in English
Capable of participating in a 90-minute face-toface interview

Any condition that may result in energy- or
fatigue-related symptoms (other than RMS)
Any condition or situation that may interfere
significantly with study participation

Stage 1: Concept elicitation
interviews
Stage 2: Cognitive
interviews

Age 18 years
RRMS diagnosis
At least 1 of the following:
1 documented relapse in the last 12 months
2 documented relapses in the last 24 months
EDSS score of 0 to 5.5 in the past 6 months
Stable course since EDSS assessment

Current treatment for an autoimmune disorder
other than MS

Stage 3: Content confirmation
interviews

Age 18 to 65 years
PRMS or RSPMS diagnosis
EDSS score of 3 to 5.5 in the past 6 months
Documented relapse during prior 12 months

Current treatment for an autoimmune disorder
other than MS
RRMS diagnosis

Stage 4: Psychometric
validation

Age 18 to 65 years
EDSS score of 0 to 5.5 in the past 1 month or at
study entry
Documented relapse during past 12 months,
excluding the month before baseline visit
Medical records available for 12 months or since
time of RMS diagnosis (if diagnosed during past
12 months)

Current treatment for an autoimmune disorder
other than MS
History of suicidal ideation
Participation in trial with investigational
medications for any condition

Stage 6: eDiary migration &
usability study

Age 18 to 55 years
EDSS score of 0 to 5.5 in the past 3 months
Documented relapse(s): 1 during past 1 year or
2 during past 2 years, excluding the 30 days
before screening

Participation in another research study within
30 days before screening
Previous participation in any study related to the
development of the FSIQ-RMS

Age 18 to 65 years
Fluent in English
Completed written ICF

Employed as a shift worker
Diagnosis of insomnia, sleep apnea, or any
disease that might cause symptoms of fatigue
Use of any medication that could cause
symptoms of fatigue
Any acute disease that is not cured
Condition that might interfere significantly with
study participation, or predicted to be unable to
comply with protocol
Participation in trial with investigational
medications for any condition

Controls
Stage 4: Psychometric
validation

EDSS, Expanded Disability Status Scale; ICF, subject information and consent form including authorization to use and disclose personal health
information for research; MS, multiple sclerosis; PRMS, progressive-relapsing MS; RMS, relapsing MS; RRMS, relapsing-remitting MS; RSPMS,
relapsing secondary-progressive MS.

addition to a real-world study conducted in Germany and the
United States, the FSIQ-RMS was administered to provide data for
a supplementary analysis of performance of the symptom items
in a real-world setting (n ¼ 154), and to assess differential item
functioning in MS patients with depression. As the real-world
study was not designed specifically to validate the FSIQ-RMS, it
is reported only briefly here, with further details provided in
Appendix 1 (see Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2018.11.007).

Stage 6: eDiary migration and usability study
The final stage was a qualitative migration and usability study in
patients with RMS in the United States (n ¼ 10) to demonstrate
readability, ease of use, acceptability of an electronic version of
the FSIQ-RMS (“eDiary”), and conceptual equivalence between
paper and electronic platforms (stage 6).
Before testing, minor changes were made to the FSIQ-RMS to
simplify the instructions (these changes were also made to the
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paper version), with additional changes to make them appropriate for administration on a handheld electronic devicedspecifically, a BLU Life Play Android smartphone. The eDiary
presented the questionnaire in landscape format with 1 item per
screen, providing more room for the horizontal numeric rating
scale and space between the responses to facilitate response
selection for MS patients who may have problems with fine
motor control.
At in-person site visits, participants received training on use of
the eDiary, and completed paper and eDiary versions of the FSIQRMS and a device-usability questionnaire with 6 questions scored
on a verbal rating scale anchored at 1 (“Very easy”) and 5 (“Very
difficult”).
One-on-one cognitive interviews were conducted to probe for
participants' interpretation of questions and response options and
their perspectives on the usability of the eDiary.

Patient Population
Other than the control participants, all participants in all study
stages had RMS diagnoses as defined by the revised McDonald
Diagnostic Criteria for MS,34 with additional subtype diagnostic
criteria for the RRMS, PRMS, and RSPMS patients. Recruitment
aimed to enroll participants generally representative of the RMS
population likely to be enrolled in future clinical trials.
As shown in Table 1, eligibility criteria were highly consistent
across study stages. Nevertheless, the upper limit of the age range for
eligibility was decreased from 65 years in early study stages to
55 years in later stages to align with the inclusion criteria in 2 phase 3
trials of ponesimod in RMS (OPTIMUM ClinicalTrials.gov identifier
NCT02425644 and POINT ClinicalTrials.gov identifier NCT02907177).

Data Analysis
For the qualitative research, participant interviews were audio
recorded, transcribed, and anonymized by a third-party transcription agency for qualitative analysis using ATLAS.ti software
(ATLAS.ti Scientific Software Development GmbH, Berlin, Germany). Initial coding schemes were developed based on the
respective interview guides. Codes were reviewed and modified by
the coders as transcripts were analyzed.
In the psychometric validation analyses, item scores were
assessed for floor and ceiling effects (ie, the clustering of item
scores at the top and bottom of the response-scale range,
respectively); a threshold of 9% of respondents in the highest or
lowest response option was applied. Item discrimination was
evaluated using the proportion of participants who endorsed a
score for each symptom item within the range of their overall
score severity across items (categorized as mild ¼ 0 to 3,
moderate ¼ 4 to 6, or severe ¼ 7 to 10), with a threshold of 50%. For
inter-item correlation analysis, item pairs with polychoric correlation coefficients of >0.8 were considered to have a high correlation.35 Because the symptoms domain was considered to
measure a unidimensional construct, only symptom items with
inter-item correlations greater than 0.90 were reviewed for potential deletion. In exploratory factor analysis, items with factor
loadings <0.40 on all factors identified were reviewed for possible
deletion.36 Internal consistency reliability was assessed by
calculating the Cronbach's alpha coefficient for each domain and
was considered to be met if the Cronbach's alpha coefficient was
>0.70.37 Evaluation of the item hierarchy and ability of the instrument to distinguish between high and low performers used
item and person separation indices and item and person reliability indices, with acceptance thresholds of >2.0 for separation
indices and >0.8 for reliability indices.38 Testeretest reliability was
assessed using the intraclass correlation coefficient (ICC), calculated using ShrouteFleiss reliability for a single score, with an ICC
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of 0.70 considered to be acceptable.39 Unidimensionality was
considered to have been demonstrated if >60% of variance was
explained by the Rasch factor and <5% was explained by the first
residual factor.40 Sufficient concurrent validity between the new
PRO instrument and other instruments was considered if the
correlation coefficient was 0.4 to 0.7.41,42 Descriptive statistical
analysis of data for the psychometric analyses was performed
using SAS (SAS Institute Inc., Cary, NC, USA). Rasch analyses were
performed with Winsteps (Linacre JM, Beaverton, OR, USA. https://
www.winsteps.com/winman/references.htm).
Quantitative results are reported as counts and percentages for
discrete variables and mean ± standard deviation (SD) for
continuous variables.

Results
Participant Characteristics
Characteristics of the participants are reported in Table 2. Across
the study stages, participants were predominantly female with
mild-to-moderate disease severity, and diverse in age, race/
ethnicity, work status (see Appendix 2 in the Supplemental
Materials found at https://doi.org/10.1016/j.jval.2018.11.007 for
additional employment details), and educational attainment.

Stage 1: Concept Elicitation Interviews in RRMS
Concept elicitation interviews were conducted with a total of 17
participants at 3 US sites in November 2010, and analyses
demonstrated that saturation was achieved.
The most commonly reported fatigue-related symptoms were
energy and weakness. Functional and emotional impacts of
fatigue-related symptoms were reported, including difficulty
walking, maintaining relationships, participating in social activities, and performing general activities of daily living, as well as
difficulty with thought processes. Elicited symptom and impact
concepts are reported in Table 3.
Based on the cognitive debriefing of the FIS, it was determined
that this instrument does not sufficiently measure fatigue-related
symptoms and their impacts on the RRMS population. The FIS is
primarily an impact instrument. Furthermore, most concepts
represented in the FIS were reported infrequently or not at all by
participants; conversely, several concepts elicited were not present in the FIS.
Based on the results of the concept elicitation interviews and
applying the above-mentioned criteria to generate items, a draft
version of the new PRO instrument was developed. Instrument
drafting also took into account evidence from the literature review
and input from clinical experts experienced in treating patients
with MS. Reasons for including or not including elicited concepts
in the draft instrument are presented in Table 3. Named the “FSIQRRMS,” the questionnaire comprised 30 items across 2 hypothesized domains: fatigue-related symptoms (n ¼ 16) and impacts of
fatigue-related symptoms (n ¼ 14).
Symptom items use an 11-point numeric rating scale assessing
the severity of each item, with response options ranging from
“Not at all” (0) to “Extremely” (10). This response scale was
selected as it is commonly used in clinical settings to assess
symptom severity. A recall period of “the past 24 hours” was
chosen because symptoms may vary between days.
Impact items use a 5-point verbal rating scale to assess the
severity or frequency of each impact, with response options
ranging from “No difficulty” to “Extreme difficulty,” “Not at all” to
“Extremely,” or “Never” to “Almost all of the time.” A numeric
rating scale was not considered appropriate for impacts because
items in the impact domain of the questionnaire assess different
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Table 2 – Patient demographic and clinical characteristics
Characteristic

RMS subtype, n (%)
RRMS
RSPMS
PRMS
Age, years, mean ± SD
(range)
Female, n (%)
Race/ethnicity, n (%)
Caucasian/white
African American/
African Caribbean/
Black
Hispanic
Asian
American Indian or
Alaskan Native
Work status, n (%)*
Working/studying
Not working
Highest level of
education, n (%)
High school diploma
or GED
Some college or
certificate program
College or university
degree
Other
MS severityy
Very mild
Mild
Moderate
Severe
EDSS score, n (%)
0.0 to 1.0
1.5 to 2.0
2.5 to 3.0
3.5 to 4.0
4.5 to 5.0
5.5 to 6.0

Stage 1:
Concept
elicitation
(N ¼ 17)

Stage 2:
Cognitive
interviews
(N ¼ 20)

17 (100)
e
e
43.9 ± 13.3
(27 to 75)
13 (76)

Stage 3: Content
confirmation

Stage 4: Psychometric
validation
RMS patients
(N ¼ 164)

Controls
(N ¼ 74)

Stage 6: eDiary
migration &
usability
study (N ¼ 10)

PRMS
(N ¼ 5)

RSPMS
(N ¼ 5)

20 (100)
e
e
47.0 ± 12.0
(25 to 69)
16 (80)

e
e
5 (100)
52.6 ± 12.5
(34 to 67)
4 (80)

e
5 (100)
e
52.4 ± 10.8
(38 to 63)
3 (60)

139 (84)
18 (11)
8 (5)
45 ± NA
(19 to 65)
124 (76)

NA
NA
NA
40 ± NA
(18 to 65)
54 (73)

8 (80)
2 (20)
0
42.1 ± 8.2
(27 to 54)
7 (70)

13 (76)
2 (12)

17 (85)
3 (15)

2 (40)
3 (60)

4 (80)
1 (20)

133 (81)
NA

56 (76)
NA

5 (50)
4 (40)

0
1 (6)
1 (6)

0
0
0

0
0
0

0
0
0

NA
NA
NA

NA
NA
NA

1 (10)
1 (10)
1 (10)

8 (47)
9 (53)

8 (40)
12 (60)

2 (40)
3 (60)

0
5 (100)

NA
NA

NA
NA

5 (50)
5 (50)

1 (6)

2 (10)

0

1 (20)

47 (29)

13 (18)

2 (20)

4 (24)

8 (40)

2 (40)

2 (40)

50 (30)

26 (35)

4 (40)

12 (71)

10 (50)

3 (60)

2 (40)

66 (40)

34 (46)

4 (40)

1 (1)

1 (1)

0

1 (6)
7 (41)
9 (53)
0

4 (20)
7 (35)
9 (45)
0

0
1 (20)
4 (80)
0

0
2 (40)
2 (40)
1 (20)

e
92 (56)
58 (35)
14 (9)

NA

0
3 (30)
7 (70)
0

4
2
4
5
1
1

4
4
4
6
0
2

e
e
0
3 (60)
2 (40)
0

e
e
0
1 (20)
0
4 (80)

23
36
36
37
32

NA

1 (10)
3 (30)
1 (10)
1 (10)
3 (30)
1 (10)

(24)
(12)
(24)
(29)
(6)
(6)

(20)
(20)
(20)
(30)
(10)

(14)
(22)
(22)
(23)
(20)

EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; NA, not available; PRMS, progressive-relapsing MS; RMS, relapsing MS;
RRMS, relapsing-remitting MS; RSPMS, relapsing secondary-progressive MS.
*
Employment details are reported in Appendix 2 in the Supplemental Materials found at https://doi.org/10.1016/j.jval.2018.11.007.
y
As assessed by patient for stages 1 to 3, 6: “Very mild,” “Mild,” “Moderate,” or “Severe;” as assessed by PGI-S MS score for stage 4: Mild ¼ 0 to 3,
Moderate ¼ 4 to 6, Severe ¼ 7 to 10.

aspects of the patient experience (eg, severity and frequency), and
so including verbal prompts for each response choice in the rating
scale was considered to be important. A 5-point scale was selected
to allow sensitivity in the response choices without adding too
much complexity for the patients.43 A recall period of “past 7 days”
was used for all impact items because impacts may not be experienced during each day of a 1-week evaluation period.

Stage 2: Cognitive Interviews in RRMS
Cognitive interviews were conducted with an additional 20 RRMS
patients at 3 US sites in February 2011. Overall, the participants

reported the draft FSIQ-RRMS instrument to be comprehensive,
understandable, and relevant. Nevertheless, participants had a few
comments, which were addressed by modifications to the draft
questionnairednamely, removal of 8 symptom items that participants did not interpret as intended (all 6 “at rest” items, which were
commonly misinterpreted, and both “exhausted” items, as
“exhausted” overlapped with other concepts and was considered by
most participants to be a more severe sensation of “tiredness”),
revision of the item stem for 6 symptom items to specify that the
fatigue symptoms were attributable to RRMS, revision of the item
stem for all impact items to specify that the impacts experienced
were attributable to fatigue, and rewording of 2 impact items to be
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Table 3 – Elicited fatigue-related symptom and impact concepts reported by participants
Concept
Symptoms
Tiredness

Frequency,
n (%)

Preliminary
decision

Rationale






15 (88.2)

Exclude

Physical tiredness

12 (70.6)

Include

Mental tiredness

6 (35.3)

Include




Fatigue

11 (64.7)

Exclude

Physical fatigue

7 (41.2)

Include






Mental fatigue

6 (35.3)

Include




Weakness

10 (58.8)

Include









Exhaustion

9 (52.9)

Exclude

Physical exhaustion

6 (35.3)

Include

Mental exhaustion

6 (35.3)

Include




Low energy

7 (41.2)

Include





Worn out/wiped out/run
down

6 (35.3)

Include





Sleepiness/Grogginess/
Drowsiness

5 (29.4)

Include




Drained

4 (23.5)

Exclude

Heaviness (physical
heaviness in limbs)

3 (17.6)

Exclude






Sluggish
Decrease in stamina
Walking
Resting/taking breaks
Having to lay down
Having to sit down
Unable to do anything/
function physically
Exercising

2 (11.8)
1 (5.9)
11 (64.7)
9 (52.9)
8 (47.1)
6 (35.3)
6 (35.3)

Exclude
Exclude
Include
Include
Exclude
Exclude
Exclude









5 (29.4)

Exclude



Difficulty standing
Lifting

3 (17.6)
3 (17.6)

Exclude
Exclude





Instrument will include items specific to physical and mental tiredness.
Concept is not mutually exclusive with “physical” and “mental” tiredness.
Concept was frequently reported by participants.
Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Concept was somewhat frequently reported by participants.
Item does not differentiate between “while doing routine daily activities”
and “while at rest” as this is not a physical concept.
Instrument will include items specific to physical and mental fatigue.
Concept is not mutually exclusive with “physical” and “mental” fatigue.
Concept was somewhat frequently reported by participants
Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Concept was somewhat frequently reported by participants
Item does not differentiate between “while doing routine daily activities”
and “while at rest” as this is not a physical concept.
Concept was somewhat frequently reported by participants.
Concept was solely reported as a physical concept by participants (ie, participants did not report weakness as a mental concept).
Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Instrument will include items specific to physical and mental exhaustion.
Concept is not mutually exclusive with “physical” and “mental” exhaustion.
Concept was somewhat frequently reported by participants.
Item divided into 2 separate questions to distinguish between the severity
of the symptom “while doing routine daily activities” and “while at rest.”
Concept was somewhat frequently reported by participants.
Item does not differentiate between “while doing routine daily activities”
and “while at rest” as this is not a physical concept.
Concept was somewhat frequently reported by participants.
Participants primarily discussed the physical impacts of energy when
defining the concept.
Participants typically discussed energy as an amount (depleted, low, or
burst of energy).
Concept was somewhat frequently reported by participants.
Participants used different words to describe this concept; however, “worn
out” was most frequently reported (n ¼ 5).
These terms were used to describe both physical and mental concepts;
therefore, no further differentiation done.
Concept was somewhat frequently reported by participants.
The term “sleepy” was reported by 3 participants; 1 participant each reported “grogginess” or “drowsiness.”
Concept was infrequently reported by participants.
Concept was inconsistently defined by participants.
Concept was infrequently reported by participants.
Reports of heaviness were specific to areas of the body that were different
for participants (eg, arms, legs, and head were all reported).
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Frequently reported
Concept was somewhat frequently reported by participants.
Concept covered by “taking breaks”
Concept covered by “taking breaks”
General concept of being unable to do anything or function physically is too
broad to be an appropriate item.
Concept overlaps with “walking” for 3 out of 5 participants who reference
this as an impact.
Concept is not a common experience, as not all patients exercise.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
continued on next page
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Table 3 – continued
Concept

Frequency,
n (%)

Preliminary
decision

Rationale

Need to push oneself
Slowed movements
Going up/down steps/stairs
Carrying
Falling
Getting in/out of the car
Relationships

3 (17.6)
3 (17.6)
2 (11.8)
1 (5.9)
1 (5.9)
1 (5.9)
10 (58.8)

Exclude
Exclude
Exclude
Exclude
Exclude
Exclude
Include










Social activities

10 (58.8)

Include




Planning

5 (29.4)

Exclude



Difficulty talking with
others
General social impact

3 (17.6)

Exclude

2 (11.8)

Exclude







Napping
Going to bed early
Difficulty falling asleep
Staying in bed
Errands

10 (58.8)
4 (23.5)
1 (5.9)
1 (5.9)
8 (47.1)

Include
Exclude
Exclude
Exclude
Include










Driving
General ADL
Daily planning

7 (41.2)
7 (41.2)
5 (29.4)

Exclude
Exclude
Include






Travel

1 (5.9)

Exclude

Indoor household
activities

8 (47.1)

Include







Outdoor household
activities

1 (5.9)

Exclude



Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was somewhat frequently reported by participants.
Participants reported different relationships being impacted, including
parent or child (n ¼ 6, 35.3%), with family (n ¼ 3, 17.6%) or social life (n ¼ 3,
17.6%) in general, husband or wife (n ¼ 2), with relation to dating (n ¼ 2,
11.8%), and boy or girlfriend (n ¼ 1, 5.9%).
Concept was somewhat frequently reported by participants.
Participants reported a variety of activities, including some that overlap
with leisure activities (eg, bowling, dancing, eating out, going to the movies),
outdoor activities (eg, going to the zoo with family), and socializing in
general (eg, speech).
Concept overlaps with “rearranging plans.” The concept as it is presented
here is a social concept, but can pertain to general activities of daily living as
well.
Concept was infrequently reported by participants.
Concept overlaps with “communicating clearly.”
Concept was infrequently reported by participants.
Participants were nonspecific in their discussion of social impacts with
these specific quotes.
Both participants who referenced a social impact with these quotes also
reported impacts on specific social activities, and 1 subject each also reported an impact on social relationships and daily planning, and so there is
potential overlap with other items measuring “social” concepts (eg, social
activities, social relationships, rearranging plans).
Concept was frequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was somewhat frequently reported by participants.
Participants reported an impact of fatigue-related symptoms on grocery
shopping (n ¼ 5, 29.4%), shopping in general (n ¼ 4, 23.5%), and running
errands (n ¼ 1, 5.9%).
Item worded to include “running errands” to capture all activities pertinent
to the concept, such as “grocery shopping” and “shopping.” While “going to
the bank or ATM” was not referenced by participants, it is a common
experience.
Concept is not a common experience, as not all patients drive a vehicle.
General concept of ADLs is too broad to be accepted as an appropriate item.
Concept was somewhat frequently reported by participants.
All 5 participants referred to having to plan their day around the severity of
their symptoms. Participants mentioned having to “manage” (n ¼ 1),
“negotiate” (n ¼ 1), and “rearrange” (n ¼ 1) plans. “Rearrange” was selected
as it was a specific impact related to planning, that would also cover the
other terms.
Concept was infrequently reported by participants.
Concept is not a common experience, as not all patients travel.
Concept was somewhat frequently reported by participants.
Participants reported difficulty performing a variety of activities (eg,
washing clothes, ironing, cooking, vacuuming).
Given that there was no consistency over the range of activities reported, no
examples were provided.
Concept was infrequently reported by participants.
continued on next page
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Table 3 – continued
Concept

Frequency,
n (%)

Preliminary
decision

Speech

7 (41.2)

Include

Thought process

7 (41.2)

Include

Memory

5 (29.4)

Include

Concentration

4 (23.5)

Exclude

Reading
Feel less alert
Mentally wiped out

4 (23.5)
1 (5.9)
1 (5.9)

Exclude
Exclude
Exclude

Frustrated/aggravated/
irritated
Motivation
Anxious/worried/nervous

5 (29.4)

Include

5 (29.4)
4 (23.5)

Include
Exclude

Feel bad/lousy/miserable

4 (23.5)

Exclude

Overwhelmed
Scared
Angry
Depressed

4
4
3
2

(23.5)
(23.5)
(17.6)
(11.8)

Exclude
Exclude
Exclude
Exclude

Embarrassed
Feel sorry for self
Disappointed
Feel like a burden
Lack of interest
Overly emotional
Sad
Bathing/washing
Productivity

2
2
1
1
1
1
1
5
5

(11.8)
(11.8)
(5.9)
(5.9)
(5.9)
(5.9)
(5.9)
(29.4)
(29.4)

Exclude
Exclude
Exclude
Exclude
Exclude
Exclude
Exclude
Include
Exclude

Schedule

5 (29.4)

Exclude

General work/school
impact

4 (23.5)

Exclude

Not working

4 (23.5)

Exclude

Rationale
 Concept was somewhat frequently reported by participants.
 Participants reported several concepts with regard to speech (eg, slurred/
slowed speech, blurting out words, talking gibberish) that all speak to difficulty articulating thoughts.
 “Communicating clearly” selected as wording to capture all areas of speech
that may be affected.
 Concept was somewhat frequently reported by participants.
 While the majority of participants referred to difficulty with their thought
“process” or “processing” information (n ¼ 4), “thinking clearly” (n ¼ 1) along
with other concepts were reported; “thinking clearly” was selected to
simplify the item while making the concept more specific.
 Concept was somewhat frequently reported by participants.
 Four participants (80.0%) used the word “forget” when reporting the
concept.
 Concept was infrequently reported by participants.
 One participant indicated that the difficulty with concentration may have
been caused by impaired vision resulting from MS, not fatigue-related
symptoms brought on by MS.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Nonspecific concept
 Concept was somewhat frequently reported by participants.
 Feeling “frustrated” was reported most often by participants (n ¼ 3, 17.6%).
 Concept was somewhat frequently reported by participants.
 Concept was infrequently reported by participants.
 “Anxiety” is a multifaceted term as it contains medical jargon and is also a
medical condition.
 Concept was infrequently reported by participants.
 General concept of feeling bad is too broad to be accepted as an appropriate
item.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept of “depression” is a multifaceted term, as it is also a medical
condition.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.
 Concept was somewhat frequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 Concept is not a common experience, as not all patients with MS are
working or going to school.
 Overlaps with “rearranging plans”
 Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 General concept of work or school is too broad to be accepted as an
appropriate item.
 Concept was infrequently reported by participants.
 Concept is not a common experience, as only some patients with MS are
working.
continued on next page
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Table 3 – continued
Concept

Frequency,
n (%)

Preliminary
decision

Attendance

2 (11.8)

Exclude

Relationships with
coworkers

2 (11.8)

Exclude

School

2 (11.8)

Exclude

Job security

1 (5.9)

Exclude

Active leisure activities
Sedentary leisure
activities
Sex life

4 (23.5)
3 (17.6)

Exclude
Exclude

2 (11.8)

Exclude

Restless legs
Sitting
Financial impact

1 (5.9)
1 (5.9)
3 (17.6)

Exclude
Exclude
Exclude

Rationale
 Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 Overlaps with “rearranging plans”
 Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are in
school.
 Concept was infrequently reported by participants.
 Concept is not a common experience, as not all patients with MS are
working.
 Broad concept that would be a secondary impact to other affected areas of
work (ie, fatigue-related symptoms of RRMS would not directly impact job
security; impact of fatigue-related symptoms of RRMS on productivity,
schedule, relationships with coworkers, etc, would impact job security).
 Concept was infrequently reported by participants.
 Concept was infrequently reported by participants.






Concept was infrequently reported by participants.
Concept is not a common experience, as not all patients are sexually active.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.
Concept was infrequently reported by participants.

ADL, activities of daily living; MS, multiple sclerosis; RRMS, relapsing-remitting MS.
Frequently reported, 11 participants; somewhat frequently reported, 5 to 10 participants; infrequently reported, 4 participants.

more specific. No revisions were required to the recall period or
response options. After revision, the PRO instrument comprised 22
items: 8 fatigue-related symptoms and 14 impacts.
Subsequently, a Rasch analysis was conducted on the participant responses collected during the stage 2 cognitive interviews.
Based on this analysis, a previously deleted symptom item was
added back to the instrument to ensure that symptoms relevant
for the severe spectrum of the disease were adequately covered,
resulting in 23 items in total.

Stage 3: Content Confirmation Interviews in PRMS, RSPMS
A total of 10 patients with PRMS (n ¼ 5) or RSPMS (n ¼ 5) were
interviewed at 2 US sites in May 2012. In the concept elicitation
portion, new concepts were reported by only 1 or 2 participants,
overlapped with already-included concepts, or were too nonspecific for inclusion in the questionnaire (eg, unable to do anything/
function physically, being in a “bad mood”). Consequently, no
items were added (nor were any other modifications made) to the
draft 23-item questionnaire, which was renamed the “FSIQ-RMS
v1.”

Stage 4: Psychometric Validation in Observational Study
Results of the psychometric analyses are summarized in Table 4.
In total, data were analyzed for 164 patients with RMS recruited
from 15 US sites and 74 controls recruited from 3 US sites, between
September 2012 and October 2013.

Instrument completion
Only 3 participants had 1 or more missing responses on symptom
items by day 8, and no symptom item had data missing from more

than 1 participant, indicating that missing data are a random effect.
The FSIQ-RMS impact items also had low levels of missing data.

Item performance analysis
Participants used the full range of the symptoms scale (0 to 10) and
the impacts scale (0 to 4), with similar distributions for all items.
Substantial ceiling effects were observed for most symptom and
impact items, reflecting the mild-to-moderate patient population
with few ambulatory limitations. Symptom items without ceiling
effects on day 1 and/or day 8 were “Physically tired,” “Physically
fatigued,” and “Energy doing routine daily activities.” The only
impact item without ceiling effects on visit 2 (day 9 to 11) was,
“How often did you have to take a break?”
High pairwise inter-item correlations (0.94) on days 1 and 8,
potentially indicating redundancy between content-related item
pairs, were observed for the symptom items “Mentally tired” and
“Mentally fatigued” and for “Physically tired” and “Physically
fatigued.” No impact item pairs had correlations >0.8 on both days
1 and 8.
The proportion of participants who endorsed a score for each
symptom item within the range of their overall score severity
across items was consistently above the 50% threshold, indicating
that the instrument is able to discriminate between mild, moderate, and severe fatigue.

Factor analysis
In exploratory factor analysis of the 9-item symptoms domain, 1
factor explained 93.4% of the variance (Eigenvalue ¼ 47.74;
P < .0001), supporting the hypothesis that the symptom items
reflect a single underlying construct. Exploratory factor analysis of
the 14-item impacts domain resulted in 3 factors explaining
9.68%, 8.37%, and 4.94% of the variance, respectively
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Table 4 – Measurement properties of the new PRO in the psychometric study.
Parameter

Rasch analysis
Person reliability
Person separation
Item reliability
Item separation
Dimensionality, %
Item misfit

Residual
correlations

Threshold for
acceptability

0.8
2.0
0.8
2.0
60
0.5 to 1.5

0.40

Measure range
Rating scale

Classical statistics
Item response and
dimensionality
analysis
Complete data
Ceiling range
Floor range
Inter-item
correlations

Item
discrimination
Factor analysis,
explained
variance

Psychometric
testing of
final
questionnaire
(reliability)
Internal
consistency
reliability

9%
9%
0.90

50%
40%

FSIQ-RMS
symptoms
domain (9-item),
observational
study, day 1
(N ¼ 164)
0.93
3.57
0.90
3.07
76.3
No item misfit by day 8.
Slight misfit for the
item “worn out at rest”
on day 1
Mentally tired and
mentally fatigued
(0.66)
Physically tired and
physically fatigued
(0.52)
0.21 to 0.38
No disordered steps
between adjacent
categories

98.2%
3.7% to 16.5%
1.8% to 9.8%
Mentally tired and
mentally fatigued
(0.95)
Physically tired and
physically fatigued
(0.95)
52% to 60%

FSIQ-RMS
symptoms domain
(7-item),
observational
study, day 1
(N ¼ 164)

FSIQ-RMS
impacts domain
(14-item),
observational
study, day 1
(N ¼ 164)

FSIQ-RMS
impacts domain
(13-item),
observational
study, day 1
(N ¼ 164)

0.91
3.19
0.92
3.49
75.0
No item misfit

0.91
3.12
0.98
6.32
59.4
No item misfit

e
e
e
e
e
e

No residual
correlations

No residual
correlations

e

0.20 to 0.37
No disordered steps
between adjacent
categories

1.26 to 1.78
No disordered
steps between
adjacent categories

Evaluated in
Stage 1 to make
item deletion
decisions. Not
evaluated on the
final measure as
the results would
be the same.

e
e
e

e
e

None

e

93.4%
(Eigenvalue ¼
47.74)

9.68%, 8.37%,
and 4.94%
(Eigenvalue ¼
19.92, 1.88, and
1.18, respectively)

0.7

0.949

Testeretest
reliability

0.7

0.928

Known-groups
validity

P < .05 for
difference in
scores between
known groups

Significant
difference in
mean scores:
Patients: 44.63
Healthy subjects: 17.67

Physical: 0.869
Cognitive/
Emotional: 0.879
Coping: 0.872
Physical: 0.946
Cognitive/
Emotional: 0.917
Coping: 0.945
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Fatigue-related Symptoms of RMS

Fatigue
• Energy
• Mentally tired
• Physically tired
• Physically weak
• Sleepy
• Worn out: activities
• Worn out: at rest
Physical Impacts
• Indoor household chores
• Rearranging plans
• Running errands
• Social activities
• Walking

Fatigue-related Impacts of RMS

Cognitive and Emotional Impacts
• Communicating clearly
• Forgetful
• Frustrated
• Maintaining relationships
• Thinking clearly
Coping Impacts
• Motivation
• Napping
• Rearranging plans*
• Social activities*
• Taking a break

Fig. 2 – Conceptual framework. RMS, relapsing multiple
sclerosis. *Items also present in physical impacts
subdomain.

(Eigenvalue ¼ 19.92, 1.88, and 1.18, respectively; P < .0001), suggesting that the impact items can be categorized into 3 conceptual
subdomains.
Rasch analysis of the 9-item symptoms domain revealed that a
unidimensional factor explaining most of the variance was “fatigue.” Rasch analysis of the 14-item impacts domain provided
evidence of multidimensionality, with the Rasch dimension
explaining 59.4% and 58.4% of the variance on days 1 and 8,
respectively, thus not reaching the threshold for demonstrating
unidimensionality.

Item reduction
Based on the observed redundancy between symptom items
measuring “fatigue” and “tired,” the items “Physically fatigued”
and “Mentally fatigued” were deleted.
The impacts item related to showering was deleted because it
had a substantial ceiling effect, with 57.9% of participants
responding that they had no difficulty showering. There was also
categorical disordering within the scale, indicating that patients
do not use the response options as intended. In addition, this item
may not be generally applicable in a multinational study because
showers may not be available in all countries.
As a result of these modifications, the final FSIQ-RMS v2
incorporated 1 hypothesized fatigue-related symptoms domain
comprising 7 items, and 3 hypothesized impacts subdomainsdphysical, cognitive/emotional, and coping (which is
combined with 2 physical impacts subdomain items)dcomprising
13 items (Fig. 2).

more severe symptoms and impacts. There is no single summary
score across the FSIQ-RMS instrument, but rather 1 symptoms
score and 3 impacts subdomain scores.
For the average weekly symptoms domain score to be
computed, data from at least 4 daily diaries with at least 4 items
(ie, 50% nonmissing item responses) completed on each day are
needed. If fewer than 4 items are reported on a day, the day is
considered missing. If fewer than 4 days are available within the
7-day period, the observation for the weekly average score is
considered missing.
For the impacts domain, the 2 items present in both the
physical and coping subdomains (“taking part in social activities”
and “rearranging plans”) are multidimensional, and represent
coping strategies related to the physical impact of the disease. For
each impacts subdomain, at least 3 items (ie, 50% nonmissing
item responses) are needed to calculate the respective weekly
subdomain score. If fewer than 3 items are reported, the observation for that week is considered missing.

Psychometric testing of final FSIQ-RMS
In confirmatory factor and Rasch analyses, the final FSIQ-RMS 7item symptoms domain demonstrated unidimensionality, with
the model explaining 75.0% of the variance on day 1 and 83.2% on
day 8. The symptoms domain was shown to contain independent,
reliable items, with item reliability indices ranging from 0.92 to
0.95 across items, exceeding the threshold for demonstrating
score repeatability. Item scores were able to discriminate patients
along the severity continuum, with item separation indices
ranging from 3.49 to 4.35, exceeding the threshold for demonstrating sensitivity of the instrument.
In analyses of concurrent validity, a higher FSIQ-RMS symptoms score wasdas expecteddassociated with lower perceived
health as measured by the RAND-36 Energy/fatigue scale on day 1,
and higher fatigue symptoms as measured by the MFIS Physical
subscale on days 1 and 2 to 8 (Table 4). All 3 impacts subdomains
were significantly correlated with the RAND-36 Role functioning/
physical scale on day 1, and the MFIS Physical and Psychosocial
subscales on days 1 and 8.
Known-groups validity was demonstrated by symptoms
domain scores differing significantly between RMS patients and
controls (Table 4).
All symptoms and impacts subdomains of the FSIQ-RMS
exceeded the threshold for internal consistency, with Cronbach's alpha on day 1 ranging from 0.869 to 0.949. All symptoms
and impacts subdomains also exceeded the threshold for
demonstrating testeretest reliability, with ICCs ranging from
0.917 to 0.946.

Attribution analysis
The differential item functioning analysis, which was performed
on the symptoms domain, found greater impairment on 3 items in
patients with RMS compared with controls, confirming significantly worse fatigue in RMS patients compared with non-RMS
individuals.
In a regression model controlling for age, cognition, and level
of depression, there was a significant 14-point difference in
symptoms score (scale range 0 to 100) between RMS patients and
controls (P < .0001), demonstrating that the fatigue-related
symptoms were attributable to RMS.

Stage 5: Real-World Study
Scoring algorithm
A scoring algorithm was developed to standardize scores on both
the symptoms domain (daily and weekly) and impacts subdomains (weekly) to a 0 to 100 scale, with higher scores indicating

Of 1597 MS patients for whom data were gathered in 2012, 154
completed the FSIQ-RMS symptoms measure and met the eligibility criteria for analysis. Results confirmed that the FSIQ-RMS
symptoms domain items met the unidimensionality and local
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independence assumptions of the Rasch model, and supported
the item reductions described above (see Appendix 1 in the
Supplementary Materials found at https://doi.org/10.1016/j.jval.2
018.11.007 for further details).

Stage 6: eDiary Migration and Usability Study
Data were analyzed for a total of 10 participants from 2 US sites
who were interviewed in January 2015. On the device-usability
questionnaire, all participants reported that it was easy or very
easy to learn, use, navigate, read, and see the response choices of
the eDiary.
In interviews, 7 participants (70%) spontaneously reported
preferring the eDiary to the paper format, based on better ease of
use (n ¼ 4), less information per page (n ¼ 2), being quicker and
simpler to use (n ¼ 3), not having to write (n ¼ 1), and providing
better flow (n ¼ 1). Participants generally interpreted the questionnaire the same way on the 2 platforms.
In the cognitive interviews, participants confirmed that the
symptoms and impacts listed on the FSIQ-RMS were relevant to
their experience with RMS. Participants generally reported understanding the meaning of the questions, instructions, and
response options, though 2 participants mentioned confusion
about the meaning of “at rest” in 1 question. After stage 6, examples were added to this question: “eg, reading a book, watching
TV.”

Discussion
Because fatigue is the most frequent symptom of MS and has a
severe impact on patients' health-related quality of life, accurate measurement of fatigue is important in devising the best
treatment strategies for each patient.44 The final FSIQ-RMS is a
valid and reliable PRO instrument that has demonstrated content and measurement validity for fatigue-related symptom
and impact items. The multistage development and psychometric validation program established that the new questionnaire measures important aspects of fatigue symptoms
attributable to relapsing forms of MS and the impacts resulting
from these symptoms.
Development and validation of the FSIQ-RMS were designed
from the outset to be rigorous with respect to current requirements for PRO instrument development. Recently, other PRO
instruments for assessing fatigue in patients with MS have been
developed following different approaches; for example, the
Neurological Fatigue Index (NFI-MS) comprises a 10-item summary scale, and scales measuring the physical and cognitive aspects of fatigue.19 In contrast to the FSIQ-RMS, the NFI-MS is based
on a fatigue-symptom framework.45
Although the FSIQ-RMS has several strengths, including
rigorous development following the FDA PRO guidance,12
incorporation of the input of RMS patients, and psychometric
validation performed in a stand-alone study that included
controls to confirm attribution of symptoms to RMS, the instrument development also has limitations. Because of the
mild-to-moderate disease of most participants, the validity of
the FSIQ-RMS in patients with more severe disease (ie, those
with EDSS >5.5) would have to be established in future
research. As the instrument has not been assessed in MS
subtypes other than RRMS, PRMS, and RSPMS, it cannot be
assumed to be applicable to patients with different disease
subtypes.
In conclusion, qualitative research and psychometric validation analyses indicate that the FSIQ-RMS is fit for purpose
for measuring fatigue symptoms and impacts as a clinical
study endpoint in RMS trials. Results of the migration and
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usability study confirmed the conceptual equivalence of the
FSIQ-RMS eDiary to the paper version and its appropriateness
for use with RMS patients. Responsiveness and meaningful
change, as well as variability by language version and demographic subgroups (eg, sex, country), of the final FSIQ-RMS
eDiary will be analyzed in 2 international phase 3 trials of
ponesimod: OPTIMUM (ponesimod vs teriflunomide in patients with active RMS; NCT02425644) and POINT (add-on
ponesimod to dimethyl-fumarate in patients with active RMS
despite treatment with dimethyl-fumarate; NCT02907177).
First results, coming from the OPTIMUM trial, are anticipated
in 2019.
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S. Hudgens, R. Schüler, J. Stokes, S. Eremenco, and E. Hunsche
contributed to study design. All authors participated in study
conception, data analysis, data interpretation, article drafting and
critical revision, and approved the final article. All authors were
involved in the decision to submit the article for publication. All
authors had full access to all of the data in this study and take
complete responsibility for the integrity of the data and the accuracy of the data analysis.

Supplemental Materials
Supplementary data associated with this article can be found in
the online version at https://doi.org/10.1016/j.jval.2018.11.007.
R E F E R E N C E S

1. Patrick E, Christodoulou C, Krupp LB, New York State MS Consortium.
Longitudinal correlates of fatigue in multiple sclerosis. Mult Scler.
2009;15:258e261.
2. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients
with multiple sclerosis. Can J Neurol Sci. 1994;21:9e14.
3. Williams AE, Vietri JT, Isherwood G, Flor A. Symptoms and association
with health outcomes in relapsing-remitting multiple sclerosis: results
of a US patient survey. Mult Scler Int. 2014;2014:203183.
4. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple
sclerosis. Nat Rev Immunol. 2015;15:545e558.
5. Smith MM, Arnett PA. Factors related to employment status changes in
individuals with multiple sclerosis. Mult Scler. 2005;11:602e609.
6. Glanz BI, Degano IR, Rintell DJ, et al. Work productivity in relapsing
multiple sclerosis: associations with disability, depression, fatigue,
anxiety, cognition, and health-related quality of life. Value Health.
2012;15:1029e1035.
7. Flensner G, Landtblom AM, Soderhamn O, Ek AC. Work capacity and
health-related quality of life among individuals with multiple sclerosis
reduced by fatigue: a cross-sectional study. BMC Public Health.
2013;13:224.
8. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis:
the impact of fatigue and depression. J Neurol Sci. 2002;205:51e58.
9. Lerdal A, Celius EG, Moum T. Fatigue and its association with
sociodemographic variables among multiple sclerosis patients. Mult
Scler. 2003;9:509e514.
10. MS Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis:
Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis.
Washington, DC: Paralyzed Veterans of America; 1998.
11. Rae-Grant A, Bennett A, Sanders AE, et al. Quality improvement in
neurology: multiple sclerosis quality measures: executive summary.
Neurology. 2015;85:1904e1908.
12. Food and Drug Administration. Guidance for Industry. Patient-reported
outcome measures: use in medical product development to support
labeling claims. http://www.fda.gov/downloads/Drugs/Guidances/
UCM193282.pdf. Accessed June 16, 2014.
13. Food and Drug Administration. Roadmap to patient-focused outcome
measurement in clinical trials. http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/DrugDevelopmentTools
QualificationProgram/ucm370177.htm. Accessed June 18, 2014.
14. Walton MK, Powers 3rd JH, Hobart J, et al. Clinical outcome
assessments: conceptual foundationdreport of the ISPOR Clinical
Outcomes AssessmentdEmerging Good Practices for Outcomes
Research Task Force. Value Health. 2015;18:741e752.
15. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity
scale. Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol. 1989;46:1121e1123.

16. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of
fatigue: initial validation of the fatigue impact scale. Clin Infect Dis.
1994;18(Suppl 1):S79eS83.
17. Meads DM, Doward LC, McKenna SP, et al. The development and
validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler.
2009;15:1228e1238.
18. Penner IK, Raselli C, Stocklin M, et al. The Fatigue Scale for Motor
and Cognitive Functions (FSMC): validation of a new instrument to
assess multiple sclerosis-related fatigue. Mult Scler.
2009;15:1509e1517.
19. Mills RJ, Young CA, Pallant JF, Tennant A. Development of a patient
reported outcome scale for fatigue in multiple sclerosis: The
Neurological Fatigue Index (NFI-MS). Health Qual Life Outcomes. 2010;8:22.
20. Barlow S, Brimelow R, Burke T, et al. Clinical evaluation of fatigue in MS
using the Brief Fatigue and Associated Symptoms Scale. Br J Neurosci
Nurs. 2016;12:216e227.
21. Mills R, Young C, Nicholas R, et al. Rasch analysis of the Fatigue Severity
Scale in multiple sclerosis. Mult Scler. 2009;15:81e87.
22. Mills RJ, Young CA, Pallant JF, Tennant A. Rasch analysis of the Modified
Fatigue Impact Scale (MFIS) in multiple sclerosis. J Neurol Neurosurg
Psychiatry. 2010;81:1049e1051.
23. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical
course of multiple sclerosis: the 2013 revisions. Neurology.
2014;83:278e286.
24. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502e1517.
25. Tremlett H, Zhao Y. Primary and secondary progressive MS have a
similar age at onset of progressiondNO. Mult Scler. 2017;23:640e642.
26. Doward LC, Meads DM, Fisk J, et al. International development of the
Unidimensional Fatigue Impact Scale (U-FIS). Value Health.
2010;13:463e468.
27. Newland P, Starkweather A, Sorenson M. Central fatigue in
multiple sclerosis: a review of the literature. J Spinal Cord Med.
2016;39:386e399.
28. Lamoureux RE, Shields A, Stokes J, et al. How many subjects are enough
for symptom-focused concept elicitation studies? A retrospective
analysis of saturation across twenty-six studies. Value Health.
2015;18:A33.
29. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey
1.0. Health Econ. 1993;2:217e227.
30. Yalcin I, Bump RC. Validation of two global impression questionnaires
for incontinence. Am J Obstet Gynecol. 2003;189:98e101.
31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology. 1983;33:1444e1452.
32. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington,
DC: Department of Health, Education, and Welfare; 1976.
33. Wild D, Grove A, Martin M, et al. Principles of Good Practice for
the Translation and Cultural Adaptation Process for PatientReported Outcomes (PRO) Measures: report of the ISPOR Task
Force for Translation and Cultural Adaptation. Value Health.
2005;8:94e104.
34. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple
sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol.
2005;58:840e846.
35. Olsson U, Drasgow F, Dorans NJ. The polyserial correlation coefficient.
Psychometrika. 1982;47:337e347.
36. Ferguson E, Cox T. Exploratory factor analysis: a users' guide. Int J Select
Assess. 1993;1:84e94.
37. Cronbach LJ. Coefficient alpha and the internal structure of tests.
Psychometrika. 1951;16:297e334.
38. Van Zile-Tamsen C. Using Rasch analysis to inform rating scale
development. Res High Educ. 2017;58:922e933.
39. Kaiser HF. The application of electronic computers to factor analysis.
Educ Psychol Meas. 1960;20:141e151.
40. Linacre JM. Data variance: explained, modeled and empirical. Rasch
Meas Trans. 2003;17:942e943.
41. Litwin MS. How to Measure Survey Reliability and Validity. Thousand Oaks,
CA: Sage; 1995.
42. Nunnally JC. The assessment of reliability. In: Bernstein I, ed.
Psychometric Theory. New York: McGraw Hill; 1994.
43. Nagata C, Ido M, Shimizu H, et al. Choice of response scale for health
measurement: comparison of 4, 5, and 7-point scales and visual analog
scale. J Epidemiol. 1996;6:192e197.
44. Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosisda
brief review. J Neurol Sci. 2012;323:9e15.
45. Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis.
QJM. 2008;101:49e60.

